● Conducting US & Korean phase 2 clinical trials for oral mucositis, and planning to enter P2 clinical study for GvHD in 2022.

● Focusing on discovering candidates derived from BIM technology and its non-clinical studies for neurodegenerative diseases.

HNSCC: Head and neck squamous cell carcinoma;   HSCT: Hematopoietic stem cell transplantation;   GvHD: Graft versus host disease;   AD: Alzheimer’s disease;   PD: Parkinson’s disease;   

FRDA: Friedreich’s Ataxia;   NASH: Non-alcoholic steatohepatitis;   IPF : Idiopathic pulmonary fibrosis